V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20124470 | 20169755 | 1.8 | 71.2 | Curative (C) | 2018-06-30 | 2018-07-17 | CABOZANTINIB | 02 | N | ECF | 100368605 |
| 20124526 | 20169756 | 1.77 | null | Palliative (P) | 2019-01-21 | 2019-06-14 | Irinotecan + Raltitrexed | 02 | null | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100138254 |
| 20124670 | 20169757 | 1.8 | 91 | null | 2021-02-10 | 2021-02-20 | null | 02 | null | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 100804200 |
| 20124931 | 20169758 | 1.58 | 79.9 | Palliative (P) | 2021-10-27 | 2021-11-05 | CAV | 02 | N | FLUOROURACIL + PANITUMUMAB | 101162702 |
| 20125058 | 20169759 | 1.75 | 72.8 | Adjuvant (A) | 2019-12-27 | 2020-01-10 | Gemcitabine + RT pancreas | 02 | N | BACILLUS CALMETTE-GUERIN | 101523786 |
| 20125581 | 20169761 | 1.8 | 15.5 | null | null | 2018-01-12 | POMALIDOMIDE | 2 | Y | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 101179710 |
| 20125986 | 20169762 | 1.8 | 84.4 | Palliative (P) | null | 2019-01-25 | BUSULFAN | N | null | ECARBOX | 100261119 |
| 20126178 | 20169764 | 1.65 | 67.7 | null | 2019-06-12 | 2019-07-27 | CAPECITABINE + LOMUSTINE | 02 | N | NILOTINIB | 101160470 |
| 20127354 | 20169767 | 1.75 | 10.8 | Palliative (P) | 2020-12-09 | 2020-12-10 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | INTERAACT TRIAL | 100668601 |
| 20127387 | 20169768 | 1.6 | 73.9 | Palliative (P) | 2020-09-14 | 2020-10-25 | ECarboX | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100568877 |
| 20128425 | 20169770 | 1.75 | 86.1 | Adjuvant (A) | 2021-01-19 | 2021-01-30 | Gemcitabine + Oxaliplatin | N | N | CAPECITABINE + STREPTOZOCIN | 101186030 |
| 20128711 | 20169772 | 1.58 | 77 | Palliative (P) | 2018-03-29 | 2018-04-14 | EOF | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101513469 |
| 20128758 | 20169773 | 1.49 | 65.6 | Palliative (P) | 2022-01-01 | 2022-01-14 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | null | TEMOZOLOMIDE | 100056430 |
| 20129164 | 20169775 | 1.53 | 67 | Palliative (P) | 2019-12-09 | 2020-01-13 | Binimetinib + Encorafenib | 02 | N | IFOSFAMIDE | 101311392 |
| 20129917 | 20169776 | 1.68 | 64 | null | 2021-10-05 | 2022-04-21 | Temozolomide + RT | 02 | null | CISPLATIN + FLUOROURACIL + STREPTOZOCIN | 101225247 |
| 20130428 | 20169777 | 1.92 | 76.2 | Palliative (P) | 2020-09-25 | 2021-06-21 | CARBOPLATIN + RT | 01 | N | CISPLATIN + FLUOROURACIL + RT | 100859039 |
| 20130468 | 20169778 | 1.55 | 74.1 | null | 2017-04-26 | 2018-02-17 | PACLITAXEL ALBUMIN (ABRAXANE) | 02 | null | CISPLATIN + FLUOROURACIL + RT | 101289378 |
| 20130606 | 20169779 | 1.79 | 69.8 | Palliative (P) | 2017-09-14 | 2017-09-26 | null | 02 | N | ATEZOLIZUMAB | 101804728 |
| 20130762 | 20169780 | 1.82 | 95.4 | Palliative (P) | 2017-07-19 | 2017-08-13 | null | 02 | N | TCX | 100789923 |
| 20131500 | 20169781 | 1.83 | 10.7 | Curative (C) | 2019-06-11 | 2020-06-22 | Hydroxycarbamide | 02 | N | CISPLATIN + RALTITREXED | 100071965 |
| 20131904 | 20169784 | 1.77 | 52.8 | Palliative (P) | 2018-12-19 | 2019-02-24 | CISPLATIN + FLUOROURACIL + RT | 02 | null | PACLITAXEL + RAMUCIRUMAB | 100112547 |
| 20131959 | 20169785 | 1.8 | 0 | null | 2019-02-21 | 2019-05-29 | SCOPE 2 TRIAL | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101090541 |
| 20132270 | 20169787 | 1.57 | 46 | Curative (C) | 2021-10-23 | 2021-10-23 | BCG Intravesical | 01 | N | CISPLATIN + FLUOROURACIL + RT | 101458958 |
| 20132504 | 20169788 | 1.71 | 68.2 | null | 2018-02-24 | 2018-02-26 | MITOMYCIN | 02 | null | ECF | 101336593 |
| 20132689 | 20169791 | 1.58 | 53 | 03 | 2018-02-20 | 2018-04-22 | Carboplatin + Vinorelbine Oral | 02 | N | DURVALUMAB | 100298501 |
| 20132768 | 20169792 | 1.5 | null | null | 2019-04-11 | 2019-04-21 | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 01 | null | ECARBOX | 100870828 |
| 20133073 | 20169793 | 1.57 | 73.6 | Curative (C) | 2016-06-15 | 2016-12-01 | ECF | 02 | N | CAPECITABINE + OXALIPLATIN + PEMBROLIZUMAB | 100460249 |
| 20133526 | 20169794 | 1.69 | 112.7 | Palliative (P) | 2020-10-14 | 2020-10-18 | Rituximab | 02 | N | CYTARABINE | 101369305 |
| 20134721 | 20169796 | 1.8 | 79.2 | null | 2019-05-17 | 2019-05-29 | Hepatoblastoma SR Cisplatin | 02 | null | OXALIPLATIN + MDG + PANITUMUMAB | 100284389 |
| 20134770 | 20169797 | null | null | null | null | 2018-10-28 | Capital Trial | N | null | CISPLATIN + FLUOROURACIL + RT | 101506005 |
| 20134872 | 20169798 | 1.79 | 0 | Neo-adjuvant (N) | null | 2016-07-07 | Pazopanib | null | N | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 101696186 |
| 20135005 | 20169799 | null | null | Curative (C) | null | 2022-04-21 | DABRAFENIB | Y | null | ARISTOTLE TRIAL | 101151596 |
| 20135121 | 20169800 | 1.72 | 51.6 | null | 2018-08-22 | 2018-08-29 | BCG Intravesical | 02 | null | INTERAACT TRIAL | 101133199 |
| 20135185 | 20169801 | 1.74 | 39.1 | Curative (C) | 2021-10-22 | 2021-12-03 | EOF | 02 | N | MELPHALAN | 101110654 |
| 20135442 | 20169802 | 1.71 | 93.5 | 03 | 2019-02-19 | 2019-06-23 | BORTEZOMIB + THALIDOMIDE | 02 | N | SCOPE2 TRIAL | 101724864 |
| 20135459 | 20169803 | 1.75 | null | null | 2019-10-27 | 2019-11-30 | MITOMYCIN | 02 | N | INTERAACT TRIAL | 101253577 |
| 20136372 | 20169804 | 1.58 | 90.6 | Palliative (P) | 2020-06-08 | 2020-06-08 | CHOP R - 21 days | 02 | N | FLUOROURACIL + PANITUMUMAB | 100360565 |
| 20137001 | 20169805 | 1.61 | 66.2 | Curative (C) | 2019-01-31 | 2019-01-31 | IRINOTECAN + MDG + PANITUMUMAB | null | N | BINIMETINIB + CETUXIMAB + ENCORAFENIB | 101120480 |
| 20137438 | 20169806 | 1.79 | 80 | Curative (C) | 2020-12-25 | 2021-01-05 | TCH (21 day Trastuzumab) Loading | 02 | N | POMALIDOMIDE | 101069527 |
| 20137533 | 20169807 | null | null | Palliative (P) | 2019-08-26 | 2020-01-08 | INTERAACT trial | 02 | N | NAB-PACLITAXEL | 101488838 |
| 20138373 | 20169809 | 1.73 | 53 | null | 2017-07-26 | 2017-08-24 | EEF or EOF | 02 | null | HYDROXYCARBAMIDE | 101440199 |
| 20138608 | 20169810 | 1.77 | 71 | null | 2017-06-21 | 2017-11-20 | CARBOPLATIN + CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 02 | N | BEVACIZUMAB + FLUOROURACIL + OXALIPLATIN | 100027479 |
| 20139650 | 20169811 | 0 | 10.1 | Palliative (P) | 2019-05-04 | 2019-06-01 | GEFITINIB | N | null | IBRUTINIB | 101453516 |
| 20139686 | 20169812 | 1.75 | 93.3 | Curative (C) | 2016-09-12 | 2016-09-28 | Epirubicin (weekly) | N | Y | EOF | 100253851 |
| 20139972 | 20169813 | 1.51 | null | 03 | 2021-01-23 | 2021-02-02 | CISPLATIN + FLUOROURACIL + RT | 02 | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 101249641 |
| 20141452 | 20169814 | 1.54 | 52 | Curative (C) | 2018-05-27 | 2018-05-27 | Topotecan (intravenous) | 02 | N | AZACITIDINE | 100507400 |
| 20141651 | 20169815 | 1.7 | 75 | null | 2017-05-29 | 2017-06-03 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100425644 |
| 20141745 | 20169816 | 1.72 | 48.1 | 03 | 2019-11-09 | 2019-11-14 | IPILIMUMAB + NIVOLUMAB | 02 | N | LETROZOLE + PALBOCICLIB | 101465889 |
| 20142471 | 20169818 | null | 86.3 | null | null | 2017-07-19 | CHOP R - 21 days | Y | null | ESPAC TRIAL | 100134933 |
| 20142578 | 20169819 | 1.5 | 15.7 | Palliative (P) | 2019-02-01 | 2019-02-04 | PHITT Trial | 02 | Y | CABAZITAXEL | 100943522 |